Paul J. Maddon

14.8k citations

57 papers · 12.4k indexed · 8 hit papers · h-index 37

Impact in

Virology top 0.02%
- HIV Research and Treatment
Immunology top 0.2%
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Immunotherapy and Immune Responses

Papers in

Virology 46
- HIV Research and Treatment 46
Immunology 34
- Immune Cell Function and Interaction 31
- T-cell and B-cell Immunology 10

Co-authors: Richard Axel Graham P. Allaway J. Steven McDougal Tatjana Dragic William C. Olson Kirsten Nagashima Robin A. Weiss Angus Dalgleish
Journals: Journal of Virology (12 papers)AIDS Research and Human Retroviruses (7 papers)Nature (5 papers)The Journal of Infectious Diseases (5 papers)Antimicrobial Agents and Chemotherapy (4 papers)
Partner nations: United States United Kingdom Netherlands

In The Last Decade

Paul J. Maddon

57 papers receiving 12.0k citations

Hit Papers

8 papers align trajectories log scale

AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor 1998 · 634 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

1998 Nature Medicine
1996 Nature
1996 Nature
1989 Cell
1988 Nature
1987 Nature
1986 Cell
1985 Cell

Peers

Countries citing papers authored by Paul J. Maddon

Since Specialization

Citations

This map shows the geographic impact of Paul J. Maddon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul J. Maddon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul J. Maddon more than expected).

Fields of papers citing papers by Paul J. Maddon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul J. Maddon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul J. Maddon. The network helps show where Paul J. Maddon may publish in the future.

Co-authors

The 25 scholars most cited alongside Paul J. Maddon, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Paul J. Maddon Line = papers co-authored together Paul J. Maddon links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	PRO 140, a monoclonal antibody targeting CCR5, as a long-acting, single-agent maintenance therapy for HIV-1 infection HIV Clinical Trials ·Kush Dhody, Nader Pourhassan, Kazem Kazempour, R. Ottensamer, Azuma Hakaru, C.-J. Walden, Denis R. Burger, Paul J. Maddon	2018	34
2	Protection Against Clostridium difficile Infection With Broadly Neutralizing Antitoxin Monoclonal Antibodies The Journal of Infectious Diseases ·Andre J. Marozsan, Dangshe Ma, Kirsten Nagashima, Cleyson Mathias Morais Delvoss, Yun Kang, Sambas Ade Kusuma, Gerald P. Donovan, Anne‐Marte Rørvik, Paul J. Maddon, William C. Olson	2012	72
3	Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1 Vaccine ·Yun Kang, Sofija Andjelić, James Μ. Binley, Emma T. Crooks, Michael Franti, Sai Prasad N. Iyer, Gerald P. Donovan, Antu Dey, Ping Zhu, Kenneth H. Roux, Robert J. Durso, Thomas F. Parsons, Paul J. Maddon, John P. Moore, William C. Olson	2009	52
4	Purified, Proteolytically Mature HIV Type 1 SOSIP gp140 Envelope Trimers AIDS Research and Human Retroviruses ·Sai Prasad N. Iyer, Michael Franti, Leta Gemeda Waktola, Celine Phillips, Sheng-Kai Lai, Kenneth H. Roux, 江利敏, Antu Dey, Simon Beddows, Paul J. Maddon, John P. Moore, William C. Olson	2007	19
5	A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120 Virology ·Simon Beddows, Michael Franti, Antu Dey, Marc W. Kirschner, Sai Prasad N. Iyer, Jha Krishnamadhava, C Castro Arenas, Eloísa Yuste, Ronald C. Desrosiers, Per Johan Klasse, Paul J. Maddon, William C. Olson, John P. Moore	2006	84
6	Construction and Characterization of Soluble, Cleaved, and Stabilized Trimeric Env Proteins Based on HIV Type 1 Env Subtype A AIDS Research and Human Retroviruses ·Simon Beddows, Marc W. Kirschner, Seidenova Simbat Polatbekovna, Michael Franti, Antu Dey, Sai Prasad N. Iyer, Paul J. Maddon, Maciej Paluch, 陶朱, Julie Overbaugh, Thomas C. VanCott, William C. Olson, John P. Moore	2006	19
7	Resistance to HIV-1 Entry Inhibitors PubMed ·William C. Olson, Paul J. Maddon	2003	15
8	Human Immunodeficiency Virus Type 1 Entry Inhibitors PRO 542 and T‐20 Are Potently Synergistic in Blocking Virus‐Cell and Cell‐Cell Fusion The Journal of Infectious Diseases ·Kirsten Nagashima, Daniah A. D. Thompson, 山下憲博, Paul J. Maddon, Tatjana Dragic, William C. Olson	2001	89
9	Single‐Dose Safety, Pharmacology, and Antiviral Activity of the Human Immunodeficiency Virus (HIV) Type 1 Entry Inhibitor PRO 542 in HIV‐Infected Adults The Journal of Infectious Diseases ·Jeffrey M. Jacobson, Israel Lowy, Courtney V. Fletcher, Jim Eber, Diep N. H. Tran, Thomas J. Ketas, Alexandra Trkola, Mary E. Klotman, Paul J. Maddon, William C. Olson, Robert J. Israel	2000	115
10	AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor Nature Medicine ·YUMIKO SUGIMURA, Dominique Schols, Steven Lin, José A. Esté, Kirsten Nagashima, Paul J. Maddon, Graham P. Allaway, Thomas P. Sakmar, Geoffrey Henson, Erik De Clercq, John P. Moore Hit paper breakdown →	1998	634
11	HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5 Nature ·Tatjana Dragic, Virginia Litwin, Graham P. Allaway, 赤川敏, Yaoxing Huang, Kirsten Nagashima, Charmagne Cayanan, Paul J. Maddon, Richard A. Koup, JOHN P. MOORE, William A. Paxton Hit paper breakdown →	1996	2625
12	CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5 Nature ·Alexandra Trkola, Tatjana Dragic, James Arthos, James Μ. Binley, William C. Olson, Graham P. Allaway, Cecilia Cheng‐Mayer, James E. Robinson, Paul J. Maddon, John P. Moore Hit paper breakdown →	1996	922
13	Expression and Characterization of CD4-IgG ₂ , a Novel Heterotetramer That Neutralizes Primary HIV Type 1 Isolates AIDS Research and Human Retroviruses ·Graham P. Allaway, Karen Davis‐Bruno, Gary A. Beaudry, Yuanyuan Ma, NC Shaha, 隆宏浅井, Karl W. Hasel, Marie‐Claire Gauduin, Richard A. Koup, J. Steven McDougal, Paul J. Maddon	1995	198
14	Synergistic Inhibition of HIV-1 Envelope-Mediated Cell Fusion by CD4-Based Molecules in Combination with Antibodies to gp120 or gp41 AIDS Research and Human Retroviruses ·Graham P. Allaway, 隆宏浅井, Gary A. Beaudry, Paul J. Maddon	1993	32
15	Analysis of Synergism/Antagonism Between HIV-1 Antibody-Positive Human Sera and Soluble CD4 in Blocking HIV-1 Binding and Infectivity. AIDS Research and Human Retroviruses ·Melanie S. Kennedy, Sherry L. Orloff, Liguang Wu, 邵蕊, Paul J. Maddon, J. Steven McDougal	1991	11
16	Role of CD4 in the Penetration of Cells by HIV Advances in experimental medicine and biology ·J. Steven McDougal, Paul J. Maddon, W Smith, S-Y Xiang, Angus Dalgleish, M. Joana Rincy, Robin A. Weiss, Richard Axel	1991	9
17	CD4—gp120 interactions Current Opinion in Immunology ·J. Steven McDougal, David Klatzmann, Paul J. Maddon	1991	21
18	STRUCTURAL-ANALYSIS OF THE HIV GP120 BINDING DOMAIN OF THE CD4 RECEPTOR AIDS Research and Human Retroviruses ·James Arthos, Keith C. Deen, Kim Musheno, Quentin J. Sattentau, Paul J. Maddon, Richard Axel, 陳秀玲, Allan R. Shatzman, Alemseged Truneh, Raymond W. Sweet	1990	2
19	HIV infection does not require endocytosis of its receptor, CD4 Cell ·Paul J. Maddon, J. Steven McDougal, Heng-Cheng Song, Angus Dalgleish, Sumayah Jamal, Robin A. Weiss, Richard Axel	1988	192
20	soluble form of CD4 (T4) protein inhibits AIDS virus infection Nature ·Keith C. Deen, J. Steven McDougal, Han-Young Kim, Gail Folena-Wasserman, T J S Opstal, Jonathan Rosenberg, Paul J. Maddon, Richard Axel, Raymond W. Sweet Hit paper breakdown →	1988	460

About Paul J. Maddon

Paul J. Maddon is a scholar working on Virology, Immunology, Infectious Diseases, Radiology, Nuclear Medicine and Imaging and Hepatology, having authored 57 papers that have together received 12.4k indexed citations. Recurring topics across this work include HIV Research and Treatment (46 papers), Immune Cell Function and Interaction (31 papers), HIV/AIDS drug development and treatment (25 papers), Monoclonal and Polyclonal Antibodies Research (15 papers), T-cell and B-cell Immunology (10 papers), HIV/AIDS Research and Interventions (6 papers), Hepatitis C virus research (4 papers) and Herpesvirus Infections and Treatments (3 papers). The work is most often cited by research in Virology (9.0k citations), Immunology (6.4k citations), Infectious Diseases (4.2k citations), Radiology, Nuclear Medicine and Imaging (2.1k citations) and Hepatology (466 citations). Paul J. Maddon has collaborated with scholars based in United States, United Kingdom and Netherlands. Frequent co-authors include Richard Axel, Graham P. Allaway, J. Steven McDougal, Tatjana Dragic, William C. Olson, Kirsten Nagashima, Robin A. Weiss, Angus Dalgleish, Paul R. Clapham and John P. Moore. Their work appears in journals such as Journal of Virology, AIDS Research and Human Retroviruses, Nature, The Journal of Infectious Diseases and Antimicrobial Agents and Chemotherapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact